维普中文期刊产品整合服务
95篇 您的检索式:作者名="Cho MY"
    题名 作者 年代 出处 被引量
1Human mannose-binding lectin and L-ficolin function as specific pattern recognition proteins in the lectin activation pathway of com- plement显示文摘Ma YG Cho MY Zhao M Park JW Matsushita M Fujita T 2004J Biol Chem2004,279,25:1
2Expression of eosinophil chemo- tactic factors in stomach cancer显示文摘Hong SW Cho MY Park C 1999Yonsei Med J1999,40,2:1
3Detection of Salmonella typhi in the blood of patients with typhoid fever by polymerase chain reaction显示文摘Song JH Cho H Park MY 1993J Clin Microbiol1993,31,6:1
4Current Trends of the Inci-dence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors ( GEP-NETs ) in Korea 2000-2009: Multicenter Study 显示文摘Gastrointestinal Pathology Study Group of Korean Society of Pathologists Cho MY Kim JM 2012Cancer Res Treat2012,44,3:1
5Effects of maternal exposure to di(2-ethylhexyl)phthalate(DEHP)during pregnancy on susceptibility to neonatal asthma显示文摘Shin IS Lee MY Cho ES 2014Toxicol Appl Pharmacol2014,274,3:1
6Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma:clinicopathologic characteristics and prognosis显示文摘Bae SY Choi MY Cho DH 2011J Breast Cancer2011,14,4:1
7Chronic Hepatitis:In Vivo Proton MR Spectroscopic Evaluation of the Liver and Correlation with Histopathologic Findings显示文摘Cho SG Kim MY Kim HJ 2001Radiology2001,221,3:1
8Analysis and Opti- mization of Passive Intermodulation in Microwave Coaxial Cavity Filters 显示文摘Cho IK Kim JT Jeong MY 2003ETRI Journal2003,25,2:1
9Long-term results after repair of complete atrioventricular septal defect with two-patch technique显示文摘Bakhtiary F Takacs J Cho MY 0,,04:1
10Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis显示文摘Bae SY Choi MY Cho DH 2011J Breast Cancer2011,14,4:1
11Modulation of telomerase activity and human telomerase reverse transcriptase expression by caspases and bcl-2 family proteins in Cisplatin-induced cell death显示文摘Park YP Choi SC Cho MY 2006Korean J Lab Med2006,26,4:1
12Three-dimensional analysis of the tooth movement and arch dimension changes in Class I malocclusions treated with first premolar extractions: a guideline for virtual treatment planning显示文摘Cho MY Choi JH Lee SP 2010Am J Orthod Dentofacial Orthop2010,138,6:1
13Diagnostic value of peripheral blood T-cell activation and soluble IL-2 receptor for acute rejection in liver transplantation显示文摘Lun A Cho MY Muller C 2002Clin Chim Acta2002,320,12:1
14Chronic hepatitis in viw) proton MR spectroscopic evaluation of the liver and correla tion with histopathologic findings 显示文摘Cho SG Kim MY Kirn HJ 2001Radiology2001,221,:1
15Therapeutic effects of fenofi- brate on diabetic peripheral neuropathy by improving endothelia and neural survival in db/db mice显示文摘Cho YR Lim JH Kim MY 2014PLoS One2014,9,83:1
16Erythropoietin increases the motility of human bone marrow-multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic fac- tors from hBM-MSCs显示文摘Koh SH Noh MY Cho GW 2009Stem Cells Dev2009,18,3:1
17An analysis of the interactions be- tween warfarin and Korean traditional herbal medicine in a Kore- an oriental hospital 显示文摘Choi D J Cho WK Kim MY 2014European Journal of Integrative Medicine2014,6,4:1
18Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments.Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis 2022Stroke & Vascular Neurology2022,7,2:1
19Crystal structure of theMycobacterium tuberculosis dUTPase: insights into the catalytic mechanism 显示文摘Chan S Segelke B Lekin T Krupka H Cho US Kim MY So M Naranjo CM Rogers YC Park MS Waldo GS Pashkov I Cascio D Perry JL Sawaya MR 2004J Mol Biol2004,341,2:1
20Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings显示文摘Cho SG Kim MY Kim HJ 2001Radiology2001,221,:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费